Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I inhaled ALX-0171 in healthy male volunteers
NL-OMON37342Phase 1Active, not recruiting
- Sponsor
- Ablynx
- Start
- Nov 2011
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing ALX-0171 with Placebo (2 arms). Primary endpoints: Plasma ALX-0171 concentrations, Pharmacokinetic parameters and 10 more. Started Nov 2011; status: active, not recruiting.
02
Drugs
gontivimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON37342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37342.